Earnings, guidance and buyback put AptarGroup in focus

AptarGroup (ATR) just released fourth quarter and full year 2025 results, issued fresh first quarter 2026 earnings guidance and unveiled a new US$600 million share repurchase program that together give investors several moving pieces to assess.

At a share price of US$141.65, AptarGroup has seen a 13.58% 1 month share price return and a 20.04% 3 month share price return. Its 1 year total shareholder return of a 2.28% decline contrasts with a 27.85% gain over three years and 17.69% over five years. This points to stronger momentum in the nearer term as investors react to the full year earnings, guidance and new buyback.

If this earnings and buyback update has you thinking more broadly about quality businesses, it could be a good moment to widen your search and check out 23 top founder-led companies.

With full year earnings up on both sales and net income, a fresh earnings outlook and a sizeable US$600 million buyback, the key question is whether AptarGroup is still undervalued or if the market is already pricing in future growth.

Most Popular Narrative: 12.3% Undervalued

With AptarGroup last closing at $141.65 against a narrative fair value of $161.43, the prevailing view is that the market is not fully reflecting its long term earnings and cash flow potential, even after the latest results and fresh buyback plans.

The rapid expansion of AptarGroup's proprietary drug delivery systems, particularly in injectables for biologics, GLP-1, and central nervous system therapies, positions the company to benefit from rising global healthcare needs and an aging population. These high-value platforms support future revenue growth and margin expansion.

Curious how that kind of product mix feeds into the $161.43 fair value estimate? Revenue, earnings and margins are all wired into this story, plus an implied future earnings multiple that assumes AptarGroup stays ahead in higher value pharma delivery platforms. The full narrative walks through those building blocks step by step so you can judge whether the assumptions stack up for you.

Result: Fair Value of $161.43 (UNDERVALUED)

However, this story can change if legal expenses remain elevated or if demand for emergency medicine and consumer healthcare products stays weaker than analysts currently expect.

Another angle on value: earnings multiple looks full

While the SWS DCF model flags AptarGroup at a discount to its estimated future cash flow value, the P/E picture is less generous. The shares trade on 23.2x earnings, compared with 22.7x for the North American packaging group, 19.3x for peers and a 19.6x fair ratio. That premium could be a cushion for quality or a source of valuation risk, depending on how you see the story playing out.

Next Steps

If this combination of earnings, valuation and buyback signals seems unclear, review the details yourself and decide promptly where you stand by checking 3 key rewards.

Looking for more investment ideas?

If you are weighing your next move after AptarGroup's update, now is the moment to broaden your watchlist and line up fresh options before others spot them.

• Target long term compounding potential by scanning for quality companies trading below their estimated worth through our 56 high quality undervalued stocks.
• Strengthen your income stream by reviewing companies with reliable payouts using our curated list of 13 dividend fortresses.
• Reduce portfolio stress by focusing on companies with healthier finances through our solid balance sheet and fundamentals stocks screener (43 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.